WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the initiation of patient enrollment in a Phase 2, open-label, single-arm, multi-center study of PDX (pralatrexate) in patients with advanced or metastatic relapsed transitional cell carcinoma (TCC) of the urinary bladder.
